EADV 2026 Update: Tulisokibart Shows Promise in Phase 2b Hidradenitis Suppurativa Trial
Late-breaking Phase 2b results for tulisokibart (MK-7240), an investigational TL1A-blocking antibody for adults with moderate-to-severe hidradenitis suppurativa.
Treatment Updates
What's new in treatment
Short summaries of newly approved therapies and important trial results, and why they matter for patients.
A Daily Pill for HS? Phase 3 Results Show Sustained Relief with Oral Povorcitinib
54-week results from the STOP-HS1 and STOP-HS2 Phase 3 trials of povorcitinib, an investigational once-daily oral JAK1 inhibitor for moderate-to-severe hidradenitis suppurativa.
New Daily Pill Matches Injectable Biologics for Plaque Psoriasis
The FDA approved icotrokinra (Icotyde), a once-daily tablet that blocks the IL-23 receptor, for adults and adolescents with moderate-to-severe plaque psoriasis.